

DAFTAR PUSTAKA

1. WHO (Mei 2018). The top 10 causes of death. <http://who.int/news-room/facts-sheets/detail/the-top-10-causes-of-death> – Diakses 14 Mei 2018.
2. Heron M, Anderson RN (Agustus 2016). Changes in the leading cause of death: Recent patterns in heart disease and cancer mortality. National Center for Health Statistic. <https://www.cdc.gov/nchs/products/databriefs/db254.htm> – Diakses 14 Mei 2018.
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide. *Int. J. Cancer.* 2015;136:E359–E386
4. Ferlay J, Shin HS, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int. J. Cancer.* 17 Juni 2010. 127(12).
5. Balitbang Kemenkes RI (2013). Riset kesehatan dasar: RISKESDAS. Jakarta: Balitbang Kemenkes RI.
6. WHO (2014). Cancer country profiles. www.who.int/cancer/country-profiles/idn_en.pdf – Diakses 14 Mei 2018
7. US National Library of Medicine (2018). Ovarian cancer. <https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0023653/> – Diakses 14 Mei 2018
8. Vijayan CP. Ovarian carcinogenesis - An Enigma. *J Gynecol.* 2016;1(5): 000126.
9. American Cancer Society (2018). Cancer facts & figures 2018. American Cancer Society. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf>. – Diakses 30 April 2018.
10. SEER (2018). Cancer stat facts: ovary cancer. National Cancer Institute. <http://seer.cancer.gov/statfacts/html/ovary.html> – Diakses 30 April 2018.
11. Balitbang Kemenkes RI (2007). Riset kesehatan dasar: RISKESDAS. Jakarta: Balitbang Kemenkes RI.

12. Dhitayoni IA, Budiana IN. Profil kanker ovarium di rumah sakit umum pusat sanglah Denpasar-bali periode juli 2013-juni2014. E-Jurnal Medika Udayana. Maret 2017;6(3).
13. Schorge JO, Joseph IS, Bradshaw K, Halvorson LM. Williams gynecology. 2nd ed. Mc Graw Hill; 2008.
14. Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, et al. Etiology and pathogenesis of epithelial ovarian cancer. Disease Markers. 2007; 23(5-6):367-76.
15. Shi LF, Yan W, Li CY. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis. Menopause. 2016 April; 23(4):417-24.
16. Zavesky L, Janzarkova N, Kohoutova M. Ovarian cancer: origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease. Neoplasia. 17 Mei 2011; 58(6):2631-42.
17. Chen VW, Ruiz B, Killeen JL, Cote RT, Wu XC, Correa CN. Pathology and classification of ovarian tumors. CANCER Supplement. 15 Mei 2003;97(10):457-68.
18. Rosen DG, Yang G, Liu G, Mercado-Urbe I, Chang B, Xiao X, et al. Ovarian cancer: pathology, biology, and disease models. Frontiers in bioscience : a journal and virtual library. 2009;14:2089-2102.
19. American Cancer Society (2018). Survival rate for ovarian cancer by stage. <https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html> – Diakses 10 September 2018
20. Barakat RR, Berchuck A, Markman M, Randall ME. Principles and practice of gynecologic oncology. 6th ed. Philadelphia (PA): Wolters Kluwer; 2015.
21. Prawirohardjo S. Buku acuan nasional ginekologi onkologi. Jakarta: YBSPB; 2006.
22. Berek JS, Hacker NF. Berek & hacker's gynecologic oncology. 6th ed. Philadelphia (PA): Wolters Kluwer; 2015.

23. Feltmate CM, Cadoo K, Viswanathan AN. Ovarian cancer. 1 Juni 2016. Cancer Network. www.cancernetwork.com/cancer-management/ovarian-cancer – Diakses 24 Agustus 2018
24. Rancourt C, Matte I, Lane D, Piche A (2012). The role of MUC16 mucin (CA125) in the pathogenesis of ovarian cancer. Ovarian Cancer- Basic Science Perspective. www.intechopen.com – Diunduh pada 24 Agustus 2018.
25. Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Couquard I. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. *Critical reviews in oncology/hematology*. 30 Agustus 2013;89(2014):2017-16.
26. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. *The Journal of Biological Chemistry*. Juli 2001;276(29):27371–5.
27. Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. *Int. J. Cancer*. April 2002;98(5): 737–40.
28. Mani R, Jamil K, Vamsy MC. Specificity of serum tumor markers (CA125, CEA, AFP, Beta HCG) in ovarian malignancies. *Trends Med. Res*. 2007;2(3):128-134.
29. Karst AM, Drapkin R. Ovarian cancer pathogenesis : a model in evolution. *J Oncol*. 2010;2010:932371.
30. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. *Gynecol Oncol*. Maret 2007;104(3):508-15.
31. Nakagawa N, Koda H, Nitta N, Nakahara Y, Uno J, Hashimoto T. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis. *Acta Med. Okayama*. 2015;69(4):227-35.
32. Snell RS. *Clinical neuroanatomy*. 7th ed. Philadelphia (PA): Wolters Kluwer; 2010.

33. Standring S, Borley NR, Gray H. Gray's anatomy: the anatomical basis of clinical practice. 40th ed., anniversary ed. Edinburgh: Churchill Livingstone; 2008.
34. Marieb EN. Human anatomy & physiology. 5th ed. San Fransisco: Benjamin Cummings; 2000.
35. Mescher AL, Junqueira LCU. Junqueira's basic histology: text and atlas. 13th ed. New York: McGraw Hill Medical; 2013.
36. Eroschenko VP, Fiore MSH. DiFiore's atlas of histology with functional correlations. 12th ed. Philadelphia: Wolters Kluwer; 2013.
37. Rambe IR, Asri A, Adrial A. Profil tumor ganas ovarium di laboratorium patologi anatomi fakultas kedokteran universitas andalas periode januari 2011 sampai desember 2012. JKA. 2014;3(1):54-7.
38. Strauss JF, Alvarez RD, Bowen DJ, Cho KR, Donovan H, et al. Ovarian cancer: evolving paradigms in research and care. Washington (DC): The National Academies Press; 2016
39. Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, et al. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet. Juli 2015;52(7):465-75.
40. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. J BP Obgyn. 2016;41(2017) 3-14.
41. Wentzensen N, Poole EM, Trabert B. Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016;34(24):2888-98.
42. Hampel H, Bennet RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. Januari 2015;17(1):70-87.
43. Kurman RJ, Shih LM. The origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory. Am J Surg Pathol. Maret 2010;34(3): 433–443.

44. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. *Nat Rev Cancer*. 2009;9:415-428.
45. Fujin C, Zhongli C, Minshan C, Yingbo C, Zhongping C, Nianji C, et al., editors. *Buku Ajar Onkologi Klinis*. Edisi 2. Jakarta: Badan Penerbit FK UI; 2013.
46. Karlan BY, Bristow RE, Andrew JL. *Gynecologic oncology clinical practice and surgical atlas*. New York: McGraw Hill; 2012.
47. Copeland L.J. *Epithelial ovarian cancer*, in: *clinical gynecologic oncology*. 7th ed. Mosby Elsevier inc; 2007.
48. Pathology Outlines (2018). Ovary tumor: clear cell carcinoma. www.pathologyoutlines.com/topic/ovarytumoreclearcell.html - Diakses 9 Oktober 2018.
49. Doubeni CA, Doubeni AA, Myers AE. Diagnosis and management of ovarian cancer. *Am Fam Physician*. 2016;93(11):937-44.
50. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, *Annals of Oncology*. 1 Oktober 2013;24(6):24-32.
51. NCCN (2017). *Clinical practice guideline in oncology: ovarian cancer*. National Comprehensive Cancer Network. www.nccn.org – Diakses 9 Oktober 2018.
52. Rarung, M. Sensitifitas dan spesifisitas petanda tumor CA125 sebagai prediksi keganasan ovarium. *JKM*. Juli 2008;8(1):9-14.
53. Jordan SM, Bristow RE. Ovarian cancer biomarkers as diagnostic triage test. *Current Biomarker Findings*. 2013;3:35-42.
54. Skates SJ, Horick N, Yu Y, Xu FJ, Berhuck A, Havrilesky LJ et al. Preoperative sensitivity and specificity for early stage ovarian cancer when combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor using mixtures of Multivariate normal distributions. *J Clin Oncol*. 2004;22:40599-4066.
55. Clarke-Pearson DL. Screening for ovarian cancer. *N Engl J Med*. 2009;361:2.

56. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. *J Clin Oncol*. 2010;28:2159-2166.
57. Budiana IN. Peran klinis CA-125 pada kanker ovarium. Denpasar: Universitas Udayana; 2014.
58. Scholler N, Urban N. CA125 in ovarian cancer. *Biomark Med*. Desember 2007;1(4):513-23.
59. Prat A, Parera M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, et al. CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. *Annals of Oncology*. 2008;19:327-331.
60. Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM. The Prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma. *Cancer*. 2009;10.1002/cncr.24084.
61. Mahner S, Woelber L, Jung S, Eulenburg CZ, Ihnen M, Schwarz J, et al. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction. *Anticancer Research*. 2009;29:2817-2822.
62. Thakur V, Anand AK, Mukherjee U, Ghosh D. Determination of cancer antigen 125 in ovarian carcinoma. *Indian J Clin Biochem*. 2003;18(2):27-33.
63. Bousquet JG, Newton AM, Chung RK, Thiel KW, Ginader T, Goodhear MJ, et al. Prediction of chemo-response in serous ovarian cancer. *Molecular cancer*. 2016;15(16):1-15.
64. Gold EB. The timing of the age at which natural menopause occurs. *Obstet Gynecol Clin North Am*. September 2011;38(3):425-40.
65. Bashir A, Sheema N, Sajid A, Shumaila B, Nourin M, Bushra G. Level and evaluation of tumor marker CA-125 in ovarian cancer patients in Khyber, Pakhtunkhwa, Pakistan. *Asian Pac J Cancer Prev*. 2015;16(1):185-9.

66. Muccluggagee WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. *Pathology*. 2011;5:420-32.
67. Reid BN, Permuth JB, Sellers TA. Epidemiology of a ovarian cancer: a review. *Cancer Biol Med*. 2017;9(1):9-31.
68. Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, et.al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. *Eur J Cancer*. Maret 2007;43(4):690-709.
69. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Webb PM. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocr Relat Cancer*. 2013;20:251–62.
70. Negri E, Pelucchi C, Franceschi S, Montella M, Conti E, Dal-Maso L, et.al. Family history of cancer and risk of ovarian cancer. *Eur J Cancer*. Maret 2003;29(4):505-10.
71. Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, Rueda BR, et.al. Correlates of the pre-operative level of CA125 at presentation of ovarian cancer. *Gynecol Oncol*. Desember 2010;119(3):462–468.
72. Khalil I, Brewer MA, Neyarapally T, Runowicz CD. The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer. *Gynecol Oncol* 2010;116(2):282–285.
73. Shah MM, Erickson BK, Matin T, McGwin G, Martind JY, Daily LB, et.al. Diabetes melitus and ovarian cancer: more complex than just increasing risk. *Gynecol Oncol*. November 2014;135(2):273–7.
74. Wang L, Wang L, Zhang J, Wang B, Liu H. Association between diabetes melitus and subsequent ovarian cancer in women: a systematic review and meta-analysis of cohort studies. *Medicine*. 2017;96:16.
75. Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F, et.al. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. *Cancer Causes Control*. Mei 2017;28(5): 469–86.

76. Kim SI, Lim MC, Lim J, Won YJ, Seo SS, Kang S, et al. Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012. *J Gynecol Oncol*. Januari 2016;27(1):e5.
77. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. *Ca Cancer J Clin* 2018;68:284–296.
78. Tiwari RK, Kaushik S, Debasis M, Chhanda D, Uttara C, Kumar GT. Evaluation of preoperative serum levels of CA 125 and expression of p53 in ovarian neoplasms: a prospective clinicopathological study in tertiary care hospital. *The J Obst Gyn India*. Maret-April 2016;66(2):107-14.
79. Ashwini NU, Shivananjaiah C, Padma K, Swarup A, dan Cherukumudi A. Correlation between the CA 125 and staging and histopathological type of ovarian cancer. *J Med Science Clin Research*. November 2015;3(11):8269-74.
80. Xu, X, Wang F, Jia L, Zhou Y, Deng F, et al. Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer. *J Ovarian Res*. 2013;1:6-31.
81. Kolwicz E, Thomas CMG, Bulten J, Massuger LF. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors. *Int J Gyn Cancer*. November 2009;19(8):1335-8.
82. Calster BV, Valentin L, Holsbeke CV, Zhang J, Jurkovic D, Zhang J, et al. A novel approach to predict the likelihood of specific ovarian tumor pathology base on serum CA-125: a multicenter observational study. *Cancer Epidemiol Biomarkers Prev*. November 2011;20(11):2420–8.
83. Yuan Q, Song J, Yang W, Wang H, Huo Q. The effect of CA125 on metastasis of ovarian cancer: old marker new function. *Oncotarget*. 2017;8(20):50015-22.
84. Henry NL, Hayes DF. Cancer biomarkers. *Mol Oncol*. April 2012;6(2):140-6.
85. Renaud MC, Plante M, Gregoire J, Roy M. Ovarian cancer in the elderly patients: are we doing enough?. *JOGC*. November 2010;1049-55.

86. Lalwani N, Prasad SR, Vikram R, Shanbhogue SK, Huettner PC, Fasih N. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. *RadioGraphics*. 2011;31:625–646.

